The Patent Finder
AS

Academia Sinica

Filings on record here from 2001, where this site's data begins
OverviewNotableFeesChangesFamiliesPatent listSources & methods

355 patents currently held

19 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Feb 2027. from the record

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
47
Ending by 2030
Feb 2027
Next term end
275
Patent families

When these terms end

Held patents by the year their term ends
notable patents fee due within 90 days all others Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.

Notable patents

Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Compositions and Methods for Treatment and Detection of Cancers US 10,150,818
The most cited patent in this portfolio, cited by 55 later US patents, top 5% of utility patents granted in 2018 in our data. Protection runs to 2035. A terminal disclaimer caps this term to an earlier patent's.
Ends Jan 2035 · Medium confidence
Also notable
Microscope-Based System and Method for Image-Guided Microscopic Illumination US 11,265,449
Cited by 5 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2038.
Ends Aug 2038 · High confidence
Also notable
Globo H and Related Anti-Cancer Vaccines with Novel Glycolipid Adjuvants US 8,268,969
Cited by 48 later US patents, top 25% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030.
Ends Jan 2030 · High confidence

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Nov 28, 2026
    The maintenance fee for Compounds for Use in Prevention and Treatment of Neurodegenerative Diseases and Pain (US 10,301,348) comes due Nov 28, 2026. Unpaid by May 28, 2027, it lapses early.
  • 12 fees due Dec 4 to 30, 2026 · next Dec 4
  • 7 fees due Jan 2 to 9, 2027 · next Jan 2
  • 9 fees due Feb 1 to 28, 2027 · next Feb 1
  • 6 fees due Mar 3 to 17, 2027 · next Mar 3
  • 5 fees due Apr 3 to 17, 2027 · next Apr 3
  • 8 fees due May 3 to 28, 2027 · next May 3
  • 5 fees due Jun 3 to 10, 2027 · next Jun 3
  • 13 fees due Jul 2 to 30, 2027 · next Jul 2
  • 3 fees due Aug 11 to 25, 2027 · next Aug 11
  • 12 fees due Sep 3 to 30, 2027 · next Sep 3
  • 5 fees due Oct 7 to 30, 2027 · next Oct 7
  • 2 fees due Nov 14 to 17, 2027 · next Nov 14

Which patents, and when each one lapses · Pro

Recent changes

  • 7 of the patents on this record were granted since Aug 22, 2026
  • 10 terms have ended since Aug 22, 2026

Patents held now

Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatusExpiresConfidence
US 7,618,938Treating Cerebrovascular Diseases with Erythropoietin and Granulocyte-Colony Stimulating Factor Jointly
In force
 · High confidence
In forceHigh confidence
US 8,597,701Transcription modulator compositions
In force
 · High confidence
In forceHigh confidence
US 7,763,285Polyacetylenic Compounds
In force
 · High confidence
In forceHigh confidence
US 8,142,999Hla Alleles Associated with Adverse Drug Reactions and Methods for Detecting Such
In force
 · High confidence
In forceHigh confidence
US 7,649,170Dual-Polarity Mass Spectrometer
In force
 · High confidence
In forceHigh confidence
US 7,547,455Cancer and Inflammatory Disorder Treatment
In force
 · High confidence
In forceHigh confidence
US 8,129,357Method of Making and Using an Adenosine Analogue
In force
 · High confidence
In forceHigh confidence
US 10,317,393Alkynyl Sugar Analogs for Labeling and Visualization of Glycoconjugates in Cells
In force
 · High confidence
In forceHigh confidence
US 8,048,455Treatment of Cancer and Inflammatory Disorder
In force
 · High confidence
In forceHigh confidence
US 7,923,007Brain Tissue Damage Therapies
In force
 · High confidence
In forceHigh confidence
10 of 355 patents shown.
Pro members see all 355.
Pro members: see all 355 patents
Also on record, not counted in the 355: 19 patents in force now held by others · 290 patents ended · 107 applications pending · 233 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited